Roche’s Tecentriq (atezolizumab) + Abraxane Receive European Commission’s Approval for Patients with PD-L1-Positive Metastatic Triple-Negative Breast Cancer

Roche’s Tecentriq (atezolizumab) + Abraxane Receive European Commission’s Approval for Patients with PD-L1-Positive Metastatic Triple-Negative Breast Cancer

Shots:

  • The approval is based on P-III IMpassion130 study assessing Tecentriq + nab-paclitaxel vs PBO + nab-paclitaxel in 902 patients in ratio (1:1) with unresectable locally advanced or metastatic TNBC treated with no prior CT for disease
  • P-III IMpassion130 study results: reduction the risk of disease worsening or death by 38%; mPFS (7.5 mos. vs 5 mos.); OS (25.0 mos. vs 18.0 mos.); no new safety signals observed. The PD-L1 status in IMpassion 130 study is assessed using VENTANA PD-L1 (SP142) assay in CE markets and available in the EU for identifying patients with TNBC eligible for treatment with the Tecentriq combination
  • Tecentriq is a mAb binds with PD-L1 protein further blocking its interaction with PD-1 and B7.1 receptor and is being evaluated in 7 trials for TNBC including early and advanced stages of the disease. Additionally, the combination with Abraxane is the first immunotherapy regimen approved in Europe for TNBC

Click here to read full press release/ article | Ref: Roche | Image: Behance